Literature DB >> 25124686

Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.

Snehal Dabir1, Amy Kluge1, Adam Kresak2, Michael Yang2, Pingfu Fu3, Bernd Groner4, Gary Wildey1, Afshin Dowlati5.   

Abstract

PURPOSE: Deregulation of STAT3 activation is a hallmark of many cancer cells, and the underlying mechanisms are subject to intense investigation. We examined the extent of PIAS3 expression in mesothelioma cells and human tumor samples and determined the functional effects of PIAS3 expression on STAT3 signaling. EXPERIMENTAL
DESIGN: We evaluated the expression of PIAS3 in mesothelioma tumors from patients and correlated the expression levels with the course of the disease. We also measured the effects of enhanced PIAS3 activity on STAT3 signaling, cellular growth, and viability in cultured mesothelioma cells.
RESULTS: Gene expression databases revealed that mesotheliomas have the lowest levels of PIAS3 transcripts among solid tumors. PIAS3 expression in human mesothelioma tumors is significantly correlated with overall survival intervals (P = 0.058). The high expression of PIAS3 is predictive of a favorable prognosis and decreases the probability of death within one year after diagnosis by 44%. PIAS3 expression is functionally linked to STAT3 activation in mesothelioma cell lines. STAT3 downregulation with siRNA or enhanced expression of PIAS3 both inhibited mesothelioma cell growth and induced apoptosis. Mesothelioma cells are sensitive to curcumin and respond by the induction of PIAS3. Corroborative evidence has been obtained from STAT3 inhibition experiments. Exposure of the cells to a peptide derived from the PIAS3 protein that interferes with STAT3 function resulted in apoptosis induction and the inhibition of cell growth.
CONCLUSION: These results suggest that PIAS3 protein expression impacts survival in patients with mesothelioma and that PIAS3 activation could become a therapeutic strategy. Clin Cancer Res; 20(19); 5124-32. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25124686     DOI: 10.1158/1078-0432.CCR-14-1233

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

1.  CD30 is a potential therapeutic target in malignant mesothelioma.

Authors:  Snehal Dabir; Adam Kresak; Michael Yang; Pingfu Fu; Gary Wildey; Afshin Dowlati
Journal:  Mol Cancer Ther       Date:  2015-01-14       Impact factor: 6.261

2.  Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry.

Authors:  Kristin J Cummings; Michael J Becich; David J Blackley; Dennis Deapen; Robert Harrison; Raffit Hassan; S Jane Henley; Mary Hesdorffer; D Kevin Horton; Jacek M Mazurek; Harvey I Pass; Emanuela Taioli; Xiao-Cheng Wu; Marjorie G Zauderer; David N Weissman
Journal:  Am J Ind Med       Date:  2019-11-19       Impact factor: 2.214

3.  Suppression of STAT3 NH2 -terminal domain chemosensitizes medulloblastoma cells by activation of protein inhibitor of activated STAT3 via de-repression by microRNA-21.

Authors:  Sutapa Ray; Don W Coulter; Shawn D Gray; Jason A Sughroue; Shrabasti Roychoudhury; Erin M McIntyre; Nagendra K Chaturvedi; Kishor K Bhakat; Shantaram S Joshi; Timothy R McGuire; John G Sharp
Journal:  Mol Carcinog       Date:  2018-01-25       Impact factor: 4.784

4.  The SUMO (Small Ubiquitin-like Modifier) Ligase PIAS3 Primes ATR for Checkpoint Activation.

Authors:  Ching-Shyi Wu; Lee Zou
Journal:  J Biol Chem       Date:  2015-11-12       Impact factor: 5.157

5.  STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Authors:  Uksha Saini; Adrian A Suarez; Shan Naidu; John J Wallbillich; Kristin Bixel; Ross A Wanner; Jason Bice; Raleigh D Kladney; Jenny Lester; Beth Y Karlan; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Cancer Res       Date:  2018-01-16       Impact factor: 12.701

Review 6.  The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of Mesothelium.

Authors:  Monica Benvenuto; Rosanna Mattera; Gloria Taffera; Maria Gabriella Giganti; Paolo Lido; Laura Masuelli; Andrea Modesti; Roberto Bei
Journal:  Nutrients       Date:  2016-05-09       Impact factor: 5.717

7.  Rosmanol induces breast cancer cells apoptosis by regulating PI3K/AKT and STAT3/JAK2 signaling pathways.

Authors:  Dongjun Jiang; Jiaqi Xu; Sitong Liu; Moussa Ide Nasser; Wei Wei; Tianjiao Mao; Xintong Liu; Xiaopan Zou; Jiang Li; Xiaomeng Li
Journal:  Oncol Lett       Date:  2021-07-01       Impact factor: 2.967

Review 8.  Regulation of Natural Killer Cell Function by STAT3.

Authors:  Nicholas A Cacalano
Journal:  Front Immunol       Date:  2016-04-11       Impact factor: 7.561

9.  The long noncoding RNA CASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer.

Authors:  Guanli Huang; Xiaoli Wu; Shi Li; Xiaoqun Xu; Hua Zhu; Xiangjian Chen
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

10.  Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy.

Authors:  Sheau-Fang Yang; Ming-Feng Hou; Fang-Ming Chen; Fu Ou-Yang; Yang-Chang Wu; Chee-Yin Chai; Yao-Tsung Yeh
Journal:  BMC Cancer       Date:  2016-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.